[{"orgOrder":0,"company":"University of Ulster","sponsor":"Ferryx Limited","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Streptococcus Thermophilus","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Ulster","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Ulster \/ Ferryx Limited","highestDevelopmentStatusID":"1","companyTruncated":"University of Ulster \/ Ferryx Limited"}]

Find Clinical Drug Pipeline Developments & Deals for Streptococcus Thermophilus

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          University of Ulster

                          Country arrow
                          BIO Partnering at JPM
                          Not Confirmed

                          University of Ulster

                          Country arrow
                          BIO Partnering at JPM
                          Not Confirmed

                          Details : Streptococcus Thermophilus is a probiotic candidate, which is currently being evaluated in clinical studies for the treatment of Gut Inflammation.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          November 28, 2025

                          Lead Product(s) : Streptococcus Thermophilus

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Ferryx Limited

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank